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Neuropeptide Y (NPY), peptide tyrosine tyrosine (PYY), and pancreatic polypeptide (PP)
are important mediators in the bidirectional communication along the gut-brain-axis.
Best known for their role in the regulation of appetite and food intake they are considered
to play a crucial role in the development of obesity. Additionally, mounting evidence
indicates a regulatory function in anxiety, mood and stress resilience with potential sex
differences. In the present study, we examined the associations of NPY, PYY, and PP
plasma levels with anxiety, depressiveness and perceived stress in obese patients. We
analyzed 144 inpatients (90 female, 54 male, BMI mean: 49.4 kg/m2) in a naturalistic
treatment setting for obesity and its somatic and mental comorbidities. Fasting
blood samples were taken, and patients completed psychometric self-assessment
questionnaires (GAD-7, PHQ-9, PSQ-20) within the first week after admission and
before discharge. Plasma concentrations of the peptides were measured by ELISA.
Women showed significant higher anxiety (GAD-7: 8.13 ± 5.67 vs. 5.93 ± 5.42,
p = 0.04) and stress scores (PSQ-20: 52.62 ± 23.5 vs. 41.23 ± 22.53, p = 0.01)
than men. In the longitudinal analysis women with a clinically relevant improvement
of anxiety (≥ 5 points on GAD-7, p < 0.001) also showed significant improvements
in depression (PHQ-9: 38%, p = 0.002) and PSQ-20 scores (23%, p = 0.005) while
anxiety-improved male patients only improved in the subscale tension of the PSQ-20
(34%, p = 0.02). In men we observed a positive correlation of PP with anxiety scores
(GAD-7: r = 0.41, p = 0.007) and with age (r = 0.49, p = 0.001) on admission while
NPY negatively correlated with age (r = -0.38, p = 0.01). In contrast, there were no
significant associations (p > 0.05) in female subjects in the cross-sectional as well as in
the longitudinal analysis. In conclusion, women suffering from morbid obesity showed
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greater psychological comorbidity and considerable interactions among them. Despite
that we solely observed associations of PP with anxiety and age with NPY and PP in
men, suggesting a possible influence of sex hormones on the NPY system. However,
improvement of anxiety scores did not lead to significant changes in NPY.
Keywords: brain-gut axis, depression, eating disorder, gut-brain axis, obesity, psychosomatic, stress, peptide YY
INTRODUCTION
Obesity, defined by the WHO as a body mass index
(BMI) ≥ 30 kg/m2 (World Health Organisation [WHO],
2020), is one of the major health problems of the 21st century.
In recent years its prevalence has increased dramatically and
thus became a global epidemic (NCDRF, 2016). Obesity is often
accompanied by other health implications including a number
of preventable chronic illnesses such as diabetes, cardiovascular
diseases and cancer that are among the leading causes of death
(GBD 2015 Obesity Collaborators Afshin et al., 2017). The
concept of energy imbalance with excess dietary calories is
considered to play a pivotal role in the development of obesity.
In modern societies prevails the unrestricted availability of
food and, therefore, human food consumption cannot solely
be attributed to self-preservation. Emerging evidence suggests
a strong impact of hedonic mechanisms in the control of food
intake which involves cognitive, reward and emotional processes
(Horwath et al., 2020).
Eating behavior is regulated by the gut-brain axis, the
bidirectional communication between the central (CNS)
and the enteric nervous system. Neural (Strandwitz, 2018),
immunological (Fung et al., 2017), endocrine (Kuhne and
Stengel, 2019) and gut microbiota-derived (Torres-Fuentes
et al., 2017) messengers are closely interrelated in the regulation
of appetite and food intake. Neuropeptide Y (NPY), peptide
tyrosine tyrosine (PYY) and pancreatic polypeptide (PP)
represent a family of peptide hormones consisting of 36 amino
acids. In humans, these peptides act with particular affinities
via four subtypes of G-protein-coupled receptors (Y1, Y2, Y4,
Y5) (Pedragosa-Badia et al., 2013) as important mediators along
the gut-brain axis. NPY is one of the most potent orexigenic
peptides that is abundantly expressed within the central and
peripheral nervous system (PNS) (Holzer et al., 2012). Centrally,
NPY displays its highest expression within hypothalamic nuclei
(Bai et al., 1985), particularly the arcuate nucleus (ARC) that
plays a key role in the regulation of hunger and satiety (Myers
and Olson, 2012). Within the gastrointestinal tract, the primary
source of NPY originates from enteric neurons (Cox, 2007).
NPY is known to influence several processes involved in energy
homeostasis, including energy intake and expenditure, physical
activity and adipose tissue function (Loh et al., 2015). PP and
PYY are postprandially released gut-derived peptides that
inhibit food intake (Field et al., 2010). PYY3−36, the biologically
active form accountable for its anorexigenic effects, is mainly
produced by intestinal L cells, whereas PP is synthesized by
endocrine F cells of the pancreatic islets (Ekblad and Sundler,
2002). The release of both peptides occurs proportionally to the
preceding caloric intake (Adrian et al., 1976, 1985) and leads to
the inhibition of orexigenic pathways in the hypothalamus (Shi
et al., 2013). PYY inhibits the release of NPY in the ARC via Y2
receptors (Ghamari-Langroudi et al., 2005), while PP preferably
binds to Y4 receptors to modulate vagal cholinergic pathways
in the brainstem (McTigue et al., 1997) and the expression of
several hypothalamic feeding-regulatory peptides (Asakawa
et al., 2003; Lin et al., 2009). Reduced circulating PYY (Batterham
et al., 2003) and PP (Marco et al., 1980) as well as elevated NPY
(Baltazi et al., 2011) levels which can be found in obese subjects
give rise to a role in the pathophysiology of obesity.
Besides controlling ingestion and energy homeostasis the
NPY family also appears to have an impact on emotional-
affective behavior. Chronic psychosocial stress is frequently
linked to obesity and metabolic disorders (Scott et al., 2012).
Mounting evidence indicates that NPY might promote some
of the underlying pathomechanisms. Particularly, stress-induced
sympathetic, glucocorticoid and hypothalamic activity leads to
upregulated NPY expression which in turn results in increased
food intake (Zakrzewska et al., 1999) and growth of abdominal
fat (Kuo et al., 2007). In addition, postprandial PYY secretion
is inhibited under conditions of psychological stress (Kiessl and
Laessle, 2016). Moreover, NPY and its receptors are broadly
expressed in brain areas, e.g., amygdala and the prefrontal cortex,
that mediate stress resilience (Kask et al., 2002).
Anxiety is a fundamental response to stress. In rodents,
NPY exerts anxiolytic effects in the amygdala, primarily via
Y1 receptor activation (Sajdyk et al., 1999), although other
receptors might be involved as well (Fendt et al., 2009). On
the contrary, stimulation of the Y2 receptor promotes an
anxiogenic response (Sajdyk et al., 2002) presumably due to
presynaptic inhibition of NPY release (Caberlotto et al., 2000).
In humans it was found that genetic variations with low-
expression NPY genotypes display a maladaptive responsiveness
to stress that predispose to major depression (Mickey et al.,
2011) and anxiety disorders (Amstadter et al., 2010). Animal
studies indicate an implication of PP and PYY in mediating
regulation of emotion, however, the underlying pathways remain
elusive. While the deletion of PYY increases depression-like
behavior but does not affect anxiety (Painsipp et al., 2011),
peripherally administered PP promotes extinction learning of
cued fear by acting on central Y4 receptors in mice (Verma
et al., 2016). However, intracerebroventricular (icv) injection
of PP does not affect anxiety (Asakawa et al., 1999) and
it is unclear whether PP is generally produced in the brain
(DiMaggio et al., 1985).
Mood and anxiety disorders are common comorbidities
among obese patients (Rajan and Menon, 2017) and
their joint occurrence is related to poorer physical and
mental quality of life (QoL) (Nigatu et al., 2016). The
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exact mechanisms of this association still warrant further
investigation of the signaling pathways involved. This is crucial
to provide a better understanding and potential treatment
options. Therefore, in the present study we investigated
the relationship between circulating levels of the members
of the NPY family (NPY, PYY, PP) and psychometrically
evaluated anxiety, depressiveness and perceived stress in obese
psychosomatic patients.
MATERIALS AND METHODS
Subjects
Within the course of a consecutive biosampling study 144 obese
inpatients (54 male, 90 female) who received medical treatment
for obesity-related somatic and mental comorbidities were
recruited upon admission to the Department of Psychosomatic
Medicine at Charité - Universitätsmedizin Berlin (between
September 2010 and December 2015). All patients were at the age
of ≥ 18 years and met the criteria for obesity with a body mass
index (BMI)≥ 30 kg/m2. Their treatment consisted of biomedical
therapy, individually adapted therapeutic exercise and both
individual and group psychotherapy as well as music and art
therapy. Patients with current pregnancy or malignant disease,
psychotic disorders, somatoform disorders of the gastrointestinal
system, preceding bariatric surgery, hypercortisolism and
untreated hypothyroidism were excluded from the study.
All patients gave written informed consent. Investigations
were conducted in accordance with the Declaration of
Helsinki; the study was approved by the institutional ethics
committee of the Charité - Universitätsmedizin Berlin (protocol
number: EA1/114/10).
Laboratory Analyses
Venous blood samples were taken after an overnight fast
between 7:00 and 8:00 AM within the first week after admission
(T0) and at a second time point during treatment (Tx).
Patients were advised not to smoke or exercise and only
to have a small amount of water before blood withdrawal.
Circulating glucose levels were determined by photometric
measurement from blood collection tubes containing sodium
fluoride that were kept at room temperature. Blood for
measuring peptide concentrations was collected in pre-cooled
standard EDTA tubes prepared with aprotinin (1.2 Trypsin
Inhibitory Unit per 1 ml blood; ICN Pharmaceuticals, Costa
Mesa, CA, United States) for peptidase inhibition. After blood
withdrawal the tubes were stored on ice and centrifuged
for 10 min at 3000 rpm at 4◦C. Plasma was separated and
samples were stored at −80◦C until further processing. NPY,
PYY and PP levels were determined using a commercial
enzyme-linked immunosorbent assay (ELISA, catalog # EK-
049-03, EK-059-02 and EK-054-02, Phoenix Pharmaceuticals,
Inc., Burlingame, CA, United States). According to the
manufacturer’s information there is no cross-reactivity (0%)
between the respective peptide antigens. All samples were
processed in one batch; the intra-assay variability was 8, 5, and
5%, respectively.
Anthropometric Measurements
Body weight and height were assessed at the same day of
blood withdrawal in patients wearing light underwear and
BMI was calculated as kg/m2. Medications and existence
of comorbidities were recorded at admission and after
hospital discharge.
Psychometric Parameters
For psychometric assessment patients were asked to complete
the following questionnaires and results obtained between
two days before and five days after the respective blood
withdrawals were accepted. Two modules of the self-
administered patient health questionnaire (PHQ) (Spitzer
et al., 1999) were used for the assessment of anxiety (GAD-7) and
depression (PHQ-9).
The generalized anxiety disorder questionnaire (GAD-7)
consists of seven items with scores ranging from “0” (not at all)
to “3” (nearly every day) with a maximum of 21 points (Spitzer
et al., 1999). The GAD-7 is an efficient tool to measure general
anxiety disorder and is also suited to detect symptoms of social
anxiety, posttraumatic stress and panic disorder (Spitzer et al.,
2006). In the present study we used the German version (Lowe
et al., 2008) that showed an internal consistency (Cronbach’s
α ) of 0.90.
The PHQ-9 depression scale is a 9-item screening
instrument for the diagnosis of major depression and the
evaluation of the severity of depressive symptoms. Total
scores range from 0–27, while the nine items represent
the DSM-IV diagnostic criteria for depressive disorders
(Spitzer et al., 1999). Our patients were handed out the
German version by Löwe et al. (2002). Cronbach’s α in the
present sample was determined as 0.88. In a meta-analysis
of 17 validation studies in different languages including
the German language translation, specificity was 0.92 and
sensitivity 0.80 for the diagnosis of a major depressive disorder
(Gilbody et al., 2007).
Evaluation of perceived stress was conducted by using the
revised 20-item German version (PSQ-20) (Fliege et al., 2005)
of the perceived stress questionnaire (PSQ; 30 items) (Levenstein
et al., 1993). Providing four subscales the PSQ assesses “worries,”
“tension,” “joy” as stress responses and “demands” as perception
of external stressors and thereby emphasizes the subjective
experience of stress. In the present sample Cronbach’s alpha for
the subscales ranged from 0.84 to 0.91.
Statistical Analyses
Data are expressed as mean ± standard deviation (SD).
Normal distribution was evaluated by the Kolmogorov-Smirnov
test. Differences between groups were calculated using t-tests
and chi-square tests. Pearson’s correlation was calculated to
assess associations of two variables. Statistical differences and
correlations were considered significant when p < 0.05. All
statistical analyses were conducted using Sigma Stat 3.1 (Systat
Software, San Jose, CA, United States).
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RESULTS
Demographic, Socioeconomic and
Medical Characteristics
The mean observation period between first (T0) and second (Tx)
blood sample and psychometric assessment was 2.3 ± 1.2 weeks
(range: 1–7 weeks). Demographic and socioeconomic
characteristics as well as comorbidities and current medications
of the study population are presented in Table 1. In the whole
study sample mean age was 46.2 ± 13.4 with a range of 19–
73 years and mean BMI was 49.1 ± 9.3 kg/m2. Men and women
did not differ regarding BMI (48.5 ± 9.3 vs. 49.5 ± 9.3 kg/m2,
p = 0.528), age (47.0 ± 14.1 vs. 45.7 ± 13.0 years, p = 0.592) and
socioeconomic characteristics (p > 0.050; Table 1). However,
significant sex differences were observed in the prevalence of
obesity-related comorbid conditions and medication. More
precisely, sleep-associated breathing disorder (p = 0.011),
hypertriglyceridemia (p = 0.007), fatty liver disease (p = 0.031)
and type 2 diabetes that requires insulin treatment (p = 0.014)
were more frequent in men. Psychopharmacological medication
was given to 33.3% of the study population with selective
serotonin reuptake inhibitors (SSRI) and selective serotonin-
norepinephrine reuptake inhibitors (SNRI) being the most
frequent pharmaceuticals (19.4%).
Baseline Patient-Reported Outcomes
In the cross-sectional analysis women showed significant higher
levels of anxiety (8.13 ± 5.67 vs. 5.93 ± 5.42, p = 0.038) and
perceived stress total scores (52.62 ± 23.5 vs. 41.23 ± 22.53,
p = 0.010) than men (Table 2). This also applied for the PSQ-
20 subscales “worries” (p = 0.005), “tension” (p = 0.015) and
“demands” (p = 0.035) but not for the subscale “joy” (p = 0.110),
while all stress subscales highly correlated with each another in
both sexes (p < 0.001).
Associations of Peptides With Age and
Anxiety
We observed a positive correlation between PP and PYY in
men (r = 0.430, p = 0.004) and women (r = 0.843, p < 0.001)
while NPY and PYY (r = 0.336, p < 0.030) were associated
solely in the male study population. On admission, in men age
was negatively associated with NPY (r = -0.378, p = 0.011) and
positively correlated with PP (r = 0.492, p < 0.001; data not
shown). Male subjects also displayed a positive correlation of PP
with GAD-7 scores (r = 0.411, p < 0.007), while NPY and PYY did
not (Figure 1). In women neither NPY, PYY nor PP correlated
with GAD-7 scores (Figure 1).
Potential Confounders
Fasting blood glucose did not significantly differ between male
and female patients (p = 0.200). Moreover, we did not find
any correlations between peptides and blood glucose levels in
male (NPY: r = -0.014, p = 0.375; PYY: r = 0.064, p = 0.688;
PP: r = 0.131, p = 0.408) nor female subjects (NPY: r = 0.031,
p = 0.804; PYY: r = 0.149, p = 0.225; PP: r = 0.182, p = 0.137).
In the whole sample 7 (4.68%) patients were taking dipeptidyl
TABLE 1 | Demographic and socioeconomic characteristics, comorbidities and
medication of study patients.
Parameter Whole population Women Men P
(n = 144) (n = 90) (n = 54)
Age (years) 46.2 ± 13.4 45.7 ± 13.0 47.0 ± 14.1 0.592
BMI (kg/m2) 49.1 ± 9.28 49.5 ± 9.28 48.5 ± 9.33 0.528
Socioeconomic characteristics
Living in a partnership 66 (45.8%) 41 (45.6%) 25 (46.3%) 0.931
Level of education 0.76
University entrance
diploma
27 (18.8%) 13 (14.4%) 14 (25.9%)
Vocational diploma 9 (6.25%) 6 (6.67%) 3 (5.56%) 0.444
Secondary education
certificate
58 (40.3%) 44 (48.9%) 14 (25.9%) 0.897
Basic school
qualification
42 (29.2%) 23 (25.6%) 19 (35.2%)
No school-leaving
qualification
8 (5.56%) 4 (4.44%) 4 (7.41%)
Currently employed 51 (35.4%) 34 (37.8%) 17 (31.5%)
Unemployment during
past 5 years
65 (45.1%) 41 (45.6%) 24 (44.4%)
Comorbidities
Binge eating disorder 21 (14.6%) 15 (16.7%) 6 (11.1%) 0.334
Sleep-associated
breathing disorder
74 (51.4%) 38 (42.2%) 36 (66.7%) 0.011
Type 2 diabetes mellitus 49 (34.0%) 27 (30.0%) 22 (40.7%) 0.188
Arterial hypertension 96 (66.7%) 56 (62.2%) 40 (74.1%) 0.144
Hypercholesterinemia 87 (60.4%) 54 (60.0%) 33 (61.1%) 0.895
Hypertriglyceridemia 40 (27.8%) 18 (20.0%) 22 (40.7%) 0.007
Hyperuricemia 65 (45.1%) 37 (41.1%) 28 (51.9%) 0.21
Fatty liver disease 91 (63.2%) 53 (58.9%) 38 (70.4%) 0.031
Medication
Insulin 15 (10.4%) 5 (5.56%) 10 (15.1%) 0.014
DPP4 inhibitors/GLP-1
analog
7 (4.86%) 3 (3.33%) 4 (7.41%) 0.271
Antidiabetics (other) 26 (18.1%) 16 (17.8%) 10 (18.5%) 0.911
Psychopharmacological
treatment
48 (33.3%) 34 (37.8%) 14 (25.9%) 0.144
Neuroleptics 17 (11.8%) 11 (12.2%) 6 (11.1%) 0.841
SSRI/SNRI 28 (19.4%) 21 (23.3%) 7 (13.0%) 0.128
Tricyclic
antidepressants
12 (8.33%) 10 (11.1%) 2 (3.70%) 0.12
Other antidepressants 10 (6.94%) 7 (7.78%) 3 (5.56%) 0.612
Tranquilizers, sedatives,
hypnotics
3 (2.08%) 2 (2.22%) 1 (1.85%) 0.88
Other
psychopharmacological
medication
7 (4.86%) 4 (4.44%) 3 (5.56%) 0.764
Statistical analysis: Data are expressed as mean ± standard deviation. Differences
between two groups were assessed using the t-test or chi-square test. Significant
differences are displayed in bold. BMI, body mass index; DPP4, dipeptidyl
peptidase-4; GLP-1, glucagon-like peptide-1; SNRI, serotonin-norepinephrine
reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor.
peptidase-4 (DPP4) antagonists as treatment for type 2 diabetes
(Table 1). Male subjects taking DPP4-inhibitors displayed
significantly lower NPY plasma concentrations (p = 0.018)
compared to patients without. After exclusion of subjects taking
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TABLE 2 | Endocrine and psychometric parameters in the cross-sectional analysis
according to sex.
Parameter Whole population Women Men P
(n= 122) (n=77) (n=45)
NPY (ng/ml) 1.31 ± 0.56 1.33 ± 0.57 1.29 ± 0.57 0.701
PP (ng/ml) 1.66 ± 0.72 1.66 ± 0.68 1.67 ± 0.78 0.929
PYY (ng/ml) 1.28 ± 0.40 1.31 ± 0.41 1.22 ± 0.37 0.244
Fasting glucose (mg/dl)
(women: n = 68; men: n =
42)
113.8 ± 40.5 108.8 ± 35.7 121.8 ± 46.7 0.104
GAD-7 7.32 ± 5.66 8.13 ± 5.67 5.93 ± 5.42 0.038
PSQ-20 total 48.4 ± 23.7 52.6 ± 23.5 41.2 ± 22.5 0.01
- Worries 46.5 ± 28.6 52.0 ± 28.4 37.2 ± 26.7 0.005
- Tension 50.9 ± 28.1 55.6 ± 27.7 42.8 ± 27.3 0.015
- Joy 44.8 ± 26.5 41.8 ± 27.0 49.8 ± 25.3 0.11
- Demands 41.0 ± 23.7 44.8 ± 23.5 34.7 ± 24.6 0.035
Statistical analysis: Data are expressed as mean ± standard deviation. Differences
between two groups were assessed using the t-test. Significant differences are
displayed in bold. BMI, body mass index; GAD-7, Generalized Anxiety Disorder
questionnaire; NPY, neuropeptide Y; PHQ-9, Patient Health Questionnaire; PP,
pancreatic polypeptide; PSQ-20, Perceived Stress Questionnaire; PYY peptide
YY(3−36).
DPP4-inhibitors the association of PP and anxiety in the male
subgroup remained significant (r = 0.427, p = 0.008).
Psychometric Parameters and Peptides
According to Changes of Anxiety
In the longitudinal analysis patients with a clinically relevant
improvement of anxiety (≥ 5 points on GAD-7, p < 0.001)
displayed significantly higher basal anxiety levels (p < 0.001) as
well as higher PHQ-9 (p < 0.001) and PSQ-20 scores (p < 0.001)
than patients with no change (± 1 point) or worsening of
anxiety (≥ 5 points on GAD-7). Regarding baseline peptide
levels, no significant differences in PP (p = 0.47) and PYY
(p = 0.09) were observed in subjects with improvement vs. no
improvement of anxiety.
Course of Psychometric Parameters,
NPY and BMI During Treatment
Over the observation period, women with an improvement of
anxiety also showed significant improvements in PHQ-9 (36%,
p = 0.002) and PSQ-20 subscales “worries” (30%, p < 0.002),
“tension” (27%, p = 0.003) as well as the total stress score
(23%, p = 0.005), while “demands” showed a trend toward an
improvement” (25%, p = 0.052; Table 3). Male patients only
improved in the subscale “tension” (34%, p = 0.024; Table 4).
In patients who did not show relevant alterations in anxiety
scores (± 1 point on GAD-7) no significant changes in other
psychometric measurements (p > 0.050) were observed. BMI did
not significantly change during the observation period in women
or men with or without an improvement of anxiety scores. Lastly,
improvement of anxiety scores did not lead to significant changes
in plasma NPY levels (p > 0.050).
DISCUSSION
While the three members of the NPY family are commonly
known as potent hunger and satiety signals (Chee and Colmers,
2008; Field et al., 2010; Loh et al., 2015) their involvement in
emotion regulatory processes has emerged as well. The aim of
the presented study was to examine the association of circulating
NPY, PYY, and PP with self-reported symptoms of anxiety,
perceived stress and depression and in obese individuals as well
as their alterations depending on the course of psychometric
measures of anxiety during inpatient treatment.
We found higher symptom severity of anxiety and stress
in female subjects compared to men, a finding in line with
our previous studies (Hofmann et al., 2015, 2017) while
another study found an increase in BMI among overweight
women with high anxiety symptomatology in GAD-7 but not
among men (Demmer et al., 2015). Additionally, women who
achieved an improvement of anxiety scores also showed a
significant reduction of depressiveness and perceived stress
during treatment. These findings likely reflect the generally
higher prevalence of depressive and anxiety disorders amongst
women (Gater et al., 1998) as well as the frequent co-occurrence
and mutual interference of these symptoms (Gros et al., 2013).
Initial anxiety scores had to be high enough to enable their
significant improvement in the first place. Consequently, patients
with a clinically relevant improvement of anxiety presented
with higher baseline levels of anxiety, depressiveness and
perceived stress. These differences were not reflected in basal
peptide concentrations.
The main finding of our study was a moderate positive
correlation of PP and anxiety scores measured by GAD-7 which
was solely observed in male subjects. The low strength of the
relationship could be due to the small sample size of the male
subgroup. In this context it is further worth mentioning that the
male study cohort was more strongly affected by obesity-related
diseases, particularly insulin dependency in type 2 diabetes
(see Table 1). Since PP has been shown to mediate glucose
homeostasis (Seymour et al., 1996) and circulating peptide
concentrations are altered in type 2 diabetic patients (Floyd et al.,
1976) we took fasting blood sugar levels as a confounding variable
into consideration. However, we did not find any correlations
between fasting blood glucose levels and PP or the other members
of the NPY family. As mentioned in the introduction, Verma
et al. (2016) described that peripheral injection of a selective Y4
agonist facilitates extinction learning of cued fear which could be
interpreted as a contradiction to our own observations. On the
other hand, PP did not affect fear acquisition and consolidation.
A conceivable explanatory approach reconciling these findings
with our own results could be that PP secretion is upregulated
under the state of anxiety. From an evolutionary point of view
anorexigenic effects of PP could benefit reduced risk-taking
behavior in face of an acute threat. However, self-limitation of
the underlying mechanisms would appear as important to assure
long-term survival which could explain why PP simultaneously
promotes extinction of conditioned fear but only in fasted and
not in fed mice. Both findings reflect the hypothesis that PP
is able to mediate anxiety-like behavior through mechanisms
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FIGURE 1 | Association between GAD-7 scores and baseline plasma levels of the neuropeptide Y family in obese psychosomatic inpatients. Correlations were
assessed between plasma neuropeptide Y (A–C), pancreatic polypeptide (D–F), and peptide YY (G–I) in the obese population of both sexes (A,D,G) and separately
for obese women (B,E,H) and men (C,F,I). Values for r and p are indicated in the figure.
from the periphery since Y4 receptors are widely expressed in
areas within reach of the peripheral blood circulation and its
peripheral administration leads to an activation of regions critical
to emotion regulation.
Laboratory analysis showed a negative correlation of age with
NPY and a positive correlation with PP in men. Current literature
suggests alterations in NPY system function with age, yet its
precise role has not been completely clarified. Studies in rodents
found age-related changes of NPY concentrations in brain
and peripheral tissues, specifically an age-induced reduction in
hypothalamic NPY (Pavia and Morris, 1994). Moreover, icv
administered NPY stimulated food intake in young rats, while
the effect diminished with increasing age up to its absence in
old rats (Akimoto and Miyasaka, 2010). However, the attenuated
responsiveness to NPY cannot be attributed to a decrease in
number and expression of hypothalamic Y1 or Y5 receptors
which are thought to mediate the orexigenic effects (Duhault
et al., 2000) since older rats display lower Y1 and Y5 mRNA levels
but an increased number of neurons transcribing Y1. This might
be due to a compensatory mechanism (Coppola et al., 2004). In
humans, NPY levels in the cerebrospinal fluid of women, but
not men, increased significantly with aging (Taniguchi et al.,
1994). It should be noted that in the present study NPY was
measured peripherally which does not necessarily reflect its
central expression. Nevertheless, consistent with our results a
prior study investigating male subjects also demonstrated a
decline of plasma NPY levels with increasing age as well as
no correlation with BMI (Chiodera et al., 2000). Lastly, our
observations match previous findings that found lower plasma PP
in adults compared to children (Hanukoglu et al., 1990).
Contrary to our expectations, we did not find a significant
association of NPY with depressiveness. In this case our results
share a number of similarities with one previous study. Using
the same tool for assessing depression (PHQ-9), Zheng et al.
(2016) also did not detect a significant correlation with circulating
NPY. However, these authors observed a positive association
of DPP4 and depressiveness alongside an inverse correlation
of NPY with increased DPP4 activity indicating their possible
interaction in the pathogenesis of depression. DPP4-mediated
proteolytic degradation of NPY and PYY results in altered
signaling and functionality of respective peptides (Elmansi et al.,
2019). A considerable proportion of our study population (34%)
suffered from type 2 diabetes, a condition in which plasma DPP4
activity is altered (Mannucci et al., 2005; McKillop et al., 2008)
and DPP4 inhibitors are commonly used oral antidiabetics. Male
subjects taking DPP4 inhibitors displayed significantly decreased
NPY levels (p = 0.02) compared with the remaining population
while all psychometric parameters and other peptide values were
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TABLE 3 | BMI, psychometric and endocrine parameters in the course of
treatment according to the changes of anxiety in women.
Before treatment After treatment % change p
No change of anxiety (± 1 point, n = 20)
GAD-7 score 6.85 ± 6.14 6.65 ± 6.12 −2.92 0.918
PHQ-9 score 8.56 ± 6.97 7.75 ± 7.03 −9.46 0.725
PSQ-20 score 50.8 ± 24.7 47.3 ± 22.5 −6.69 0.634
- Worries 47.7 ± 26.4 39.7 ± 29.9 −16.8 0.371
- Tension 52.7 ± 28.2 49.0 ± 26.9 −7.02 0.676
- Joy 47.0 ± 29.2 45.0 ± 23.9 −4.26 0.814
- Demands 50.0 ± 24.4 45.3 ± 22.8 −9.4 0.536
NPY (ng/ml) 1.11 ± 0.53 0.98 ± 0.45 −11.7 0.41
BMI (kg/m2) 48.7 ± 8.57 47.8 ± 8.33 −1.85 0.744
Improvement of anxiety (≥ 5 points, n = 25)
GAD-7 score 13.4 ± 4.46 5.88 ± 3.72 −56 <0.001
PHQ-9 score 13.4 ± 5.01 8.65 ± 4.99 −35.5 0.002
PSQ-20 score 68.1 ± 19.2 52.3 ± 18.6 −23.1 0.005
- Worries 72.8 ± 25.1 50.9 ± 19.8 −30 0.001
- Tension 73.9 ± 21.1 53.6 ± 24.7 −27.4 0.003
- Joy 30.4 ± 24.4 37.1 ± 20.3 + 21.9 0.299
- Demands 56.0 ± 26.7 41.9 ± 23.5 −25.3 0.052
NPY (ng/ml) 1.15 ± 0.44 1.04 ± 0.35 −9.79 0.32
BMI (kg/m2) 49.5 ± 9.51 48.5 ± 8.99 −2.12 0.691
It is to note that three patients showed a worsening of their anxiety (≥ 5 points);
however, the n of this group was too small in order to perform meaningful
comparisons; therefore these data are not shown in this table. Statistical analysis:
Data are expressed as mean ± standard deviation. Differences between two
measurements were assessed using the t-test. Significant differences are displayed
in bold. BMI, body mass index; GAD-7, Generalized Anxiety Disorder questionnaire;
NPY, neuropeptide Y; PHQ-9, Patient Health Questionnaire; PSQ-20, Perceived
Stress Questionnaire.
not affected. After excluding subjects taking DPP4 inhibitors
association of PP and anxiety remained significant which concurs
well with previous results that found PP secretion to be unaffected
by DPP4 inhibition (Veedfald et al., 2015). However, DPP4
activity correlates with various parameters which are altered
within the course of metabolic syndrome (Lamers et al., 2011).
Therefore, we cannot exclude that lacking correlations between
other peptides and psychometric measurements were caused by
varying manifestations and severity of obesity-related disorders
in the study population.
Another investigation indicated decreased NPY plasma
concentrations in patients with major depressive disorder
compared to healthy controls (Hashimoto et al., 1996).
Incongruous evidence might be attributed to the co-occurrence
of obesity and depression that are opposingly interrelated with
NPY and conceivably offset one another. Indeed, the former
study observed a positive association between NPY and BMI
(Zheng et al., 2016) which has not been observed here, which
might be due to antidepressants and concomitant diseases
acting as confounding factors. Particularly, SSRI and SNRI
which constituted the most frequent psychopharmacological
medications taken by our study participants have been shown to
interact with NPY (Lee et al., 2016).
NPY is known to be involved in the stress reaction
(Reichmann and Holzer, 2016). Even though we did not find a
TABLE 4 | BMI, psychometric and endocrine parameters in the course of
treatment according to the changes of anxiety in men.
Before treatment After treatment % change p
No change of anxiety (± 1 point, n = 17)
GAD-7 score 3.5 ± 3.30 3.00 ± 3.34 −13.6 0.676
PHQ-9 score 5.56 ± 5.01 4.35 ± 4.55 −21.8 0.451
PSQ-20 score 34.8 ± 20.9 31.9 ± 20.2 −8.46 0.687
-Worries 31.0 ± 22.5 25.5 ± 20.4 −17.7 0.414
-Tension 36.5 ± 25.5 31.0 ± 24.0 −15.1 0.553
-Joy 57.3 ± 24.4 58.8 ± 27.5 + 2.74 0.861
-Demands 29.0 ± 22.5 29.8 ± 21.6 + 2.70 0.877
NPY (ng/ml) 0.94 ± 0.41 0.83 ± 0.33 −11.1 0.425
BMI (kg/m2) 48.1 ± 7.01 46.9 ± 6.59 −2.65 0.588
Improvement of anxiety (≥ 5 points, n = 12)
GAD-7 score 10.8 ± 3.91 3.33 ± 2.93 −69 <0.001
PHQ-9 score 11.4 ± 6.92 7.40 ± 5.60 −35.2 0.156
PSQ-20 score 59.7 ± 24.8 43.5 ± 23.8 −27.2 0.116
- Worries 55.6 ± 30.4 34.4 ± 28.6 −38 0.093
- Tension 69.4 ± 23.9 45.6 ± 24.4 −34.4 0.024
- Joy 33.3 ± 20.9 41.1 ± 27.8 +23.3 0.447
- Demands 47.2 ± 34.9 35.0 ± 24.0 −25.9 0.328
NPY (ng/ml) 0.94 ± 0.36 0.74 ± 0.22 −21.4 0.114
BMI (kg/m2) 50.8 ± 11.4 49.5 ± 11.3 −2.54 0.783
Statistical analysis: Data are expressed as mean ± standard deviation. Differences
between two measurements were assessed using the t-test. Significant differences
are displayed in bold. BMI, body mass index; GAD-7, Generalized Anxiety Disorder
questionnaire; NPY, neuropeptide Y; PHQ-9, Patient Health Questionnaire; PSQ-
20, Perceived Stress Questionnaire.
significant correlation between NPY and perceived stress in our
study population, a statistically significant negative association
with the PSQ subscale “joy” was only narrowly missed in
men. According to its validation study the subscale joy reflects
individual resources and is positively correlated with QoL (Fliege
et al., 2005). Thus, NPY may play a role in mediating stress
resilience, a hypothesis to be further investigated.
Remarkably, female subjects did not show any correlation
between peptides and other variables in the present study.
Observed sex differences could be explained by disparities in
hormonal status. Specifically, estradiol exhibits an inhibitory
effect on NPY expression in the ARC of female rats (Reboucas
et al., 2016), while increased NPY levels under estrogen
deficiency, for instance during menopause, led to hyperphagia
and body weight gain (Ainslie et al., 2001). In order to eliminate
the impact of medical treatment as a potentially confounding
factor in the cross-sectional analysis sample collection was carried
out at the beginning of the hospital stay. Thus, an adjustment for
menstrual cycle phase in female subjects was not feasible.
Contrary to our hypothesis, improvement of anxiety scores
did not lead to significant changes in circulating NPY levels which
was the main focus of this study. Other members of the NPY
family were not determined in the longitudinal analysis which
should be further investigated in the future with respect to the
observed association of PP with anxiety scores in men.
Further limitations of the present study are noteworthy.
First, all psychometric measurements used self-assessment
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questionnaires. Despite the substantial advantages of reflecting
the subjectively perceived state of emotional aspects and
their easy implementation, self-report data bears the risk
of inaccuracy due to recall bias, social desirability and
difficulties in introspective ability. Secondly, the study population
predominantly consisted of morbidly obese patients, a condition
that frequently entails a considerable number of comorbidities
that in turn might act as confounding variables. Third, since we
chose a naturalistic study design that usually does not provide a
control group, therefore no healthy normal weight subjects were
included. The naturalistic design can either be seen as a limitation
or a strength. The low degree of standardization in return favors a
higher ecological validity. Compared with randomized controlled
trials (RCTs) our investigations allow a more comprehensive
picture which fits the biopsychosocial approach that is widely
acknowledged in the field of psychosomatic medicine. However,
it is important to note that no causality can be drawn from
our findings since the influence of confounding and interaction
effects cannot be entirely eliminated. Lastly, it cannot be excluded
that the employed immunoassays recognized certain degradation
products of the targeted peptides next to their biologically active
forms. Especially with regard to PYY, C-terminal truncation
of PYY3−36 to PYY3−34 entails the loss of its bioactivity in
regulating energy homeostasis (Lafferty et al., 2018). Nonetheless,
in the event of an upregulation as observed in PP associated
with anxiety, we would expect increased levels of both active
as well as inactive forms. Besides, psychometric assessment
tools for anxiety and depression used in the present study
evaluate symptom severity during the past two weeks while
PSQ-20 assesses the patients general experience of stress. As we
did not aim to examine acute emotional responses the exact
determination of biologically active forms would not appear to
be of utmost importance.
Taken together, current data support the concept of the gut-
brain axis as bidirectional interplay of peripheral and central
signals in the regulation of behavioral patterns essential for
survival. In this case the role of the gut-derived PP in the
regulation of anxiety is particularly noteworthy, although other
factors are very likely to affect this association as well. Peptides of
the NPY family are involved in multiple physiological pathways
and thus being influenced by many different variables. Our
findings emphasize especially age and conceivably sex hormones
as distinct contributing factors. Further research employing
normal-weight controls as well as the consideration of hormonal
status or menstrual cycle phase are required to better understand
the role of NPY, PYY and PP in the pathophysiology of obesity
and the emotional response to stress.
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